Sacituzumab Tirumotecan Combined With Pembrolizumab Improves Outcomes in PD-L1 Positive NSCLC
Trial shows combination therapy improves survival in lung cancer
A Phase 3 trial shows that adding sacituzumab tirumotecan to pembrolizumab significantly extends progression-free survival in advanced NSCLC…
A new drug combination significantly extends the time patients with advanced lung cancer live without their disease progressing.
Elevated troponin levels are associated with increased risk of MACE and all-cause mortality in ICI-associated myocarditis
Troponin levels help identify heart inflammation in cancer patients
This meta-analysis evaluates the performance of cardiac troponin as a biomarker for identifying immune checkpoint inhibitor (ICI)-associated…
A new look at cardiac troponin shows it can help doctors spot and predict serious heart risks for patients on certain cancer treatments.
Anti-PD-1 based chemo-immunotherapy for nasopharyngeal carcinoma yields objective response rates of 20 to 91 percent
New Research Explores Treatments for Nasopharyngeal Carcinoma
This narrative synthesis reviews 182 studies regarding the mechanisms and treatments for nasopharyngeal carcinoma. It highlights that anti-P…
New research explores how immunotherapy and targeted treatments can improve outcomes for patients with nasopharyngeal carcinoma.
Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
New data shows better survival for liver cancer patients
This systematic review and network meta-analysis of 8,138 patients evaluated immune-based combinations versus monotherapies for advanced hep…
New research highlights how specific immune-based drug combinations can improve survival rates for people with advanced liver cancer.
Undetectable baseline ctDNA significantly improves progression-free and overall survival in advanced NSCLC patients
Tumor DNA Levels Help Predict Outcomes in Lung Cancer Treatment
This meta-analysis of 2,107 patients evaluates the role of circulating tumor DNA (ctDNA) as a biomarker for outcomes in advanced NSCLC treat…
Testing for circulating tumor DNA may help doctors predict how well patients with advanced lung cancer respond to immunotherapy treatments.
Evolocumab reduces MACE by 29% in patients with BMI greater than or equal to 35 kg/m
Evolocumab shows greater heart protection for patients with higher BMI
This randomized controlled trial of 27,564 stable atherosclerotic cardiovascular disease patients found that evolocumab significantly reduce…
A large study finds that the heart medication evolocumab provides significantly more protection against heart attacks and strokes for patien…
Bibliometric analysis maps research trends and key contributors in immune checkpoint inhibitors for endometrial cancer
Mapping the Research Landscape of Immune Therapy for Endometrial Cancer
This systematic review uses a bibliometric analysis to map the landscape of immune checkpoint inhibitor research in endometrial cancer. The …
A large-scale analysis maps out how researchers worldwide are studying immune checkpoint inhibitors to treat endometrial cancer.
Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…
Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
A single patient remains disease-free after a new chemo-immunotherapy approach for rare breast cancer
This case report describes a 71-year-old woman with triple-negative neuroendocrine breast cancer treated with paclitaxel, cisplatin, and pem…
A 71-year-old woman with rare breast cancer stayed disease-free for a year using a combination of chemotherapy and immunotherapy that doctor…
PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
Immunotherapy combo extends life in advanced endometrial cancer
A meta-analysis of 4,052 patients from RCTs found that adding PD-1/PD-L1 inhibitors to chemotherapy improved overall survival (median 43.7 v…
Adding immunotherapy to chemo boosted survival by over 14 months in advanced endometrial cancer, a new analysis finds.
Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
Skin reactions in lung cancer patients may signal longer life with certain treatments
This meta-analysis evaluated patients with non-small cell lung cancer receiving anti-PD-1, PD-L1, or chemotherapy. The analysis found that c…
A large review found that specific skin reactions linked to cancer drugs are connected to longer survival times for some lung cancer patient…
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…